These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35419865)

  • 1. Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy.
    Li ZY; Shen QH; Mao ZW; Tan CP
    Chem Asian J; 2022 Jul; 17(13):e202200270. PubMed ID: 35419865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
    Lazarević T; Rilak A; Bugarčić ŽD
    Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metallo-Drugs in Cancer Therapy: Past, Present and Future.
    Lucaciu RL; Hangan AC; Sevastre B; Oprean LS
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Anticancer Ruthenium Complexes in Drug Discovery and Medicinal Chemistry.
    Thota S
    Mini Rev Med Chem; 2016; 16(10):771. PubMed ID: 27161007
    [No Abstract]   [Full Text] [Related]  

  • 5. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
    Abid M; Shamsi F; Azam A
    Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metal Complexes in Cancer Treatment: Journey So Far.
    Kumar Singh A; Kumar A; Singh H; Sonawane P; Pathak P; Grishina M; Pal Yadav J; Verma A; Kumar P
    Chem Biodivers; 2023 Apr; 20(4):e202300061. PubMed ID: 36824028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preface.
    Prudhomme M
    Anticancer Agents Med Chem; 2017; 17(1):3. PubMed ID: 28143384
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
    Liu P; Jia J; Zhao Y; Wang KZ
    Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
    Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
    Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New applications of old metal-binding drugs in the treatment of human cancer.
    Schmitt SM; Frezza M; Dou QP
    Front Biosci (Schol Ed); 2012 Jan; 4(1):375-91. PubMed ID: 22202066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphoroorganic Metal Complexes in Therapeutics.
    Demkowicz S; Kozak W; Daśko M; Rachon J
    Mini Rev Med Chem; 2016; 16(17):1359-1373. PubMed ID: 27145849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhodamine-modified fluorescent half-sandwich iridium and ruthenium complexes: potential application as bioimaging and anticancer agents.
    Ma W; Guo L; Tian Z; Zhang S; He X; Li J; Yang Y; Liu Z
    Dalton Trans; 2019 Apr; 48(15):4788-4793. PubMed ID: 30892340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent development of transition metal complexes with in vivo antitumor activity.
    Liang JX; Zhong HJ; Yang G; Vellaisamy K; Ma DL; Leung CH
    J Inorg Biochem; 2017 Dec; 177():276-286. PubMed ID: 28641893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing the gaps in homeostatic mechanisms of copper and copper dithiocarbamate complexes in cancer therapy: a shift from classical platinum-drug mechanisms.
    Njenga LW; Mbugua SN; Odhiambo RA; Onani MO
    Dalton Trans; 2023 May; 52(18):5823-5847. PubMed ID: 37021641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application as Potent Anticancer Agents.
    Du Q; Guo L; Ge X; Zhao L; Tian Z; Liu X; Zhang F; Liu Z
    Inorg Chem; 2019 May; 58(9):5956-5965. PubMed ID: 30986046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of fluorine and Naphthyridine-Based half-sandwich organoiridium/ruthenium complexes with bioimaging and anticancer activity.
    Li J; Tian Z; Ge X; Xu Z; Feng Y; Liu Z
    Eur J Med Chem; 2019 Feb; 163():830-839. PubMed ID: 30579123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luminescent and Photofunctional Transition Metal Complexes: From Molecular Design to Diagnostic and Therapeutic Applications.
    Lee LC; Lo KK
    J Am Chem Soc; 2022 Aug; 144(32):14420-14440. PubMed ID: 35925792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.